RR No. 18-2020 clarifies VAT exemption for approved prescription medicines, key disease categories, effective dates, and import VAT refund rules.

Manufacturers, distributors, wholesalers, retailers, importers, hospitals, pharmacies, and corporate taxpayers dealing in covered prescription medicines must immediately review their VAT treatment because RR No. 18-2020 confirms that certain drugs and medicines are VAT-exempt, but only if they fall within the approved Department of Health list and only for the diseases and dates specified in the regulation. The most urgent compliance point is that prescription drugs and medicines for diabetes, high cholesterol, and hypertension are treated as VAT-exempt beginning January 1, 2020, while the VAT exemption for prescription drugs and medicines for cancer, mental illness, tuberculosis, and kidney diseases begins on January 1, 2023.

What RR No. 18-2020 Changed

RR No. 18-2020 implements Section 1 of Republic Act No. 11467, which further amended Section 109(AA) of the National Internal Revenue Code of 1997, as amended by the TRAIN Law. The regulation amends Section 4.109-1 of Revenue Regulations No. 16-2005, as previously amended by RR No. 13-2018, by expanding and clarifying the VAT exemption for the sale or importation of specific prescription drugs and medicines.

The covered VAT-exempt transactions are the sale or importation of prescription drugs and medicines for diabetes, high cholesterol, hypertension, cancer, mental illness, tuberculosis, and kidney diseases. This matters to businesses because VAT exemption changes invoicing, pricing, importation cost, VAT return treatment, input tax accounting, and refund strategy. A seller or importer cannot simply treat all medicines as VAT-exempt. The exemption is disease-specific, date-specific, and list-specific.

Covered Drugs and Dates of VAT Exemption

RR No. 18-2020 provides two important effective dates for the VAT exemption. First, the sale or importation of prescription drugs and medicines for diabetes, high cholesterol, and hypertension is VAT-exempt beginning January 1, 2020. Second, the sale or importation of prescription drugs and medicines for cancer, mental illness, tuberculosis, and kidney diseases is VAT-exempt beginning January 1, 2023.

For pharmaceutical companies, importers, pharmacies, hospitals, distributors, and wholesalers, these dates should be mapped against sales invoices, import entries, VAT returns, and internal accounting records. The January 1, 2020 date is especially important for diabetes, high cholesterol, and hypertension medicines because it affects transactions that may already have been recorded, sold, imported, or reported before the issuance and effectivity of the regulation.

Who Is Most Affected

The taxpayers most affected by RR No. 18-2020 are manufacturers, distributors, wholesalers, and retailers of prescription drugs and medicines, including pharmacy chains, hospital pharmacies, drug importers, and businesses involved in pharmaceutical distribution. Corporate buyers, hospitals, health maintenance organizations, clinics, and accounting teams that process medicine purchases should also take note because VAT-exempt treatment affects supplier invoices and whether VAT should be recognized as input tax.

The regulation is also directly relevant to importers of prescription drugs and medicines for diabetes, high cholesterol, and hypertension. RR No. 18-2020 contains a transitory refund rule for VAT paid on importation from the effectivity of Republic Act No. 11467 on January 27, 2020 until the effectivity of the regulations, provided that the imported medicines are included in the Department of Health-Food and Drug Administration approved list and the input tax has not been reported and claimed as input tax credit in monthly or quarterly VAT returns.

Approved DOH List Requirement

The VAT exemption does not apply automatically to every medicine used for the listed diseases. RR No. 18-2020 expressly limits the exemption to the sale or importation by manufacturers, distributors, wholesalers, and retailers of drugs and medicines included in the list of approved drugs and medicines issued by the Department of Health for this purpose.

This list requirement is a critical compliance control. Businesses should not rely only on a product description, internal classification, physician usage, or general commercial category. The covered drug or medicine must be in the approved DOH list. For tax teams, the practical issue is documentation: the company should maintain a file showing that the specific product sold or imported is covered by the approved list applicable to the VAT-exempt transaction.

VAT Refund Rule for Importers

RR No. 18-2020 provides a transitory rule for VAT on importation of prescription drugs and medicines for diabetes, high cholesterol, and hypertension included in the DOH-FDA approved list. VAT paid on these imports from January 27, 2020 until the effectivity of RR No. 18-2020 may be refunded pursuant to Section 204(C) of the Tax Code of 1997, as amended, and in accordance with existing procedures for refund of VAT on importation.

However, the refund is subject to an important condition: the input tax on the imported items must not have been reported and claimed as input tax credit in the monthly and/or quarterly VAT returns. RR No. 18-2020 also states that the same VAT shall not be allowed as input tax credit under Section 110 of the Tax Code for purposes of computing the VAT payable of the concerned taxpayers for the period. In practical terms, an importer must choose the proper treatment and must avoid a double benefit. If the VAT was claimed as input tax credit, it cannot also be refunded under the transitory provision.

Compliance Requirements and Practical Deadlines

Businesses should immediately identify all products in their inventory, import records, and sales records that fall under the covered disease categories. For diabetes, high cholesterol, and hypertension medicines, review transactions beginning January 1, 2020 for sales and importation treatment, and separately review import VAT paid from January 27, 2020 until the effectivity of RR No. 18-2020 for possible refund treatment.

For cancer, mental illness, tuberculosis, and kidney disease medicines, the key date is January 1, 2023. Businesses should ensure that from that date onward, covered products included in the DOH-approved list are properly treated as VAT-exempt. Accounting teams should coordinate with regulatory, procurement, pharmacy, and importation teams to ensure that the VAT classification in the enterprise resource planning system, invoicing system, and import documentation is consistent with RR No. 18-2020.

RR No. 18-2020 states that it takes effect immediately following publication in leading newspapers of general circulation. The regulation itself is dated June 26, 2020. For companies reviewing historical VAT treatment, the relevant dates are therefore the statutory exemption dates, the January 27, 2020 effectivity of Republic Act No. 11467 for purposes of the import VAT transitory refund, and the publication-based effectivity of the regulation.

Penalties and Tax Risks for Non-Compliance

RR No. 18-2020 does not create a separate special penalty provision. However, incorrect VAT treatment may still create material tax exposure under the Tax Code and BIR audit procedures. If a business improperly treats a non-covered drug as VAT-exempt, it may face deficiency VAT exposure, interest, surcharge, and compromise penalties under applicable tax rules. If a business improperly claims input VAT on imported items that should be subject to the refund rule and not treated as input tax credit, the BIR may disallow the input tax claim.

The opposite error can also be costly. If a business charges VAT on a transaction that should be VAT-exempt, pricing, customer billing, and return filing may need correction. Importers that paid VAT on qualifying imports during the transitory period may lose refund opportunities if they fail to document the claim, if they already reported and claimed the VAT as input tax credit, or if they do not follow existing procedures for VAT refund on importation.

Practical Steps for Businesses

First, classify all prescription drugs and medicines by disease category and determine whether each product is included in the DOH-approved list. Second, segregate products for diabetes, high cholesterol, and hypertension from products for cancer, mental illness, tuberculosis, and kidney diseases because the applicable exemption dates are different. Third, review sales invoices, official receipts, import entries, VAT returns, and accounting entries for transactions beginning January 1, 2020 and, where applicable, January 1, 2023.

Fourth, importers should review whether VAT was paid on qualifying diabetes, high cholesterol, and hypertension medicines from January 27, 2020 until the effectivity of RR No. 18-2020. If so, determine whether the amount was claimed as input tax credit. If it was not claimed as input tax credit, the company should assess whether a refund under Section 204(C) of the Tax Code is available under existing procedures. Fifth, update tax codes in accounting systems so that VAT-exempt medicines are not mistakenly treated as VATable sales or as purchases with creditable input VAT.

How Ablola, Saribong & Gueco Can Help

RR No. 18-2020 is especially important for businesses in the pharmaceutical, healthcare, hospital, importation, and retail pharmacy sectors because a single product classification error can affect VAT billing, importation costs, input tax claims, and BIR audit exposure. Ablola, Saribong & Gueco assists clients in reviewing VAT treatment, preparing documentation for VAT-exempt transactions, assessing import VAT refund options, and responding to BIR audit issues involving pharmaceutical and healthcare-related tax compliance.

For businesses that sell, distribute, import, or purchase prescription drugs and medicines for diabetes, high cholesterol, hypertension, cancer, mental illness, tuberculosis, or kidney diseases, ASG Law can help determine the proper tax treatment under RR No. 18-2020 and related BIR rules. For assistance with BIR compliance, VAT exemption review, or import VAT refund strategy, visit MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *